Financials in USD. Standardized financial statements.
A compact view of how Mangoceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue? | $456,021 | $615,873 | $731,493 | $8,939 | $0 |
| Revenue Growth? | -26.0% | -15.8% | +8083.2% | 0.0% | 0.0% |
| Cost of Revenue? | $205,635 | $235,909 | $299,992 | $4,089 | $0 |
| Gross Profit? | $250,386 | $379,964 | $431,501 | $4,850 | $0 |
| Gross Margin? | +54.9% | +61.7% | +59.0% | +54.3% | 0.0% |
| Operating Expenses? | $19.41M | $8.35M | $9.65M | $2.00M | $17,520 |
| Operating Income? | -$19.15M | -$7.97M | -$9.22M | -$1.99M | -$17,520 |
| EBITDA? | -$18.82M | -$7.96M | -$8.09M | -$1.99M | -$17,520 |
| Income Before Tax | -$20.64M | -$8.71M | -$9.21M | -$2.00M | -$17,701 |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$20.64M | -$8.71M | -$9.21M | -$2.00M | -$17,701 |
| EPS? | $-2.05 | $-4.40 | $-8.58 | $-1.73 | $-0.02 |
| Diluted EPS? | $-2.05 | $-4.40 | $-8.58 | $-1.73 | $-0.02 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality